Atypical Neuroleptic Malignant Syndrome: Case Reports and Diagnostic Challenges

References

• Adityanjee, Y., A. Aderibigbe, and T. Mathews. 1999. Epidemiology of neuroleptic malignant syndrome. Clinical Neuropharmacology 22:151–58.
   PubMed Web of Science ®Google Scholar
• Adityanjee, Y. A. 1991. The myth of elevated serum creatine phosphokinase level and neuroleptic malignant syndrome. British Journal of Psychiatry 158 (5):706–07. doi:10.1192/bjp.158.5.706.
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. 2013. Diagnostic and statistical manual of mental disorders. 5th ed. (DSM-5). Washington, DC. American Psychiatric Association.
   Google Scholar
• Ananth, J., S. Parameswaran, S. Gunatilake, K. Burgoyne, and T. Sidhom. 2004. Neuroleptic malignant syndrome and atypical antipsychotic drugs. The Journal of Clinical Psychiatry 65 (4):464–70. doi:10.4088/jpc.v65n0403.
   PubMed Web of Science ®Google Scholar
• Anzai, T., K. Takahashi, and M. Watanabe. 2019. Adverse reaction reports of neuroleptic malignant syndrome induced by atypical antipsychotic agents in the Japanese adverse drug event report (JADER) database. Psychiatry and Clinical Neurosciences 73 (1):27–33. doi:10.1111/pcn.12793.
   PubMed Web of Science ®Google Scholar
• Ayyildiz, H., S. Turan, D. Gulcu, C. A. Poryaz, E. Pehlivanoglu, F. Cullu, and M. K. Arikan. 2016. Olanzapine-induced atypical neuroleptic malignant syndrome in an adolescent man with anorexia nervosa. Eating and Weight Disorders - Studies on Anorexia, Bulimia and Obesity 21 (2):309–11. doi:10.1007/s40519-015-0247-3.
   PubMed Web of Science ®Google Scholar
• Beach, S. R., C. M. Celano, P. A. Noseworthy, J. L. Januzzi, and J. C. Huffman. 2013. QTc prolongation, torsades de pointes, and psychotropic medications. Psychosomatics 54 (1):1–13. doi:10/1016/j.psym.2012.11.001.
   PubMed Web of Science ®Google Scholar
• Berardi, D., M. Dell’Atti, M. Amore, D. De Ronchi, and G. Ferrari. 2002. Clinical risk factors for neuroleptic malignant syndrome. Human Psychopharmacology: Clinical and Experimental 17 (2):99–102. doi:10.1002/hup.376.
   PubMed Web of Science ®Google Scholar
• Berman, D. B., and M. Brian. 2011. Neuroleptic malignant syndrome: A review for neurohospitalists. The Neurohospitalist 1 (1):41–47. doi:10.1177/1941875210386491.
   PubMedGoogle Scholar
• Caroff, S. N., and S. C. Mann. 1998. Neuroleptic malignant syndrome. Psychopharmacology Bulletin 24:25–29.
   Google Scholar
• Carroll, B., and S. Surber. 2009. The problem of atypical neuroleptic malignant syndrome: A case report. Psychiatry 6:45–47.
   PubMedGoogle Scholar
• Changsu, H., L. Soo-Jung, and P. Chi-Un. 2011. Paliperidone-associated atypical neuroleptic malignant syndrome: A case report. Progres in Neuro-Psychopharmacology & Biological Psychiatry 35 (2):650–51. doi:10.1016/j.pnpbp.2010.12.006.
   PubMed Web of Science ®Google Scholar
• Chen, Y. T., K. P. Su, and J. P. Chang. 2011. Early detection and management of atypical neuroleptic malignant syndrome secondary to aripiprazole. Schizophrenia Research 132 (1):97–98. doi:10.1016/j.pnpbp.2010.12.006.
   PubMed Web of Science ®Google Scholar
• Cherry, S., D. Siskind, and V. Spivak. 2016. Fever, confusion, acute kidney injury: Is this atypical neuroleptic malignant syndrome following polypharmacy with clozapine and risperidone? Australasian Psychiatry 24 (6):602–03. doi:10.1177/1039856216649768.
   PubMed Web of Science ®Google Scholar
• Duma, S. R., and V. Fung. 2019. Drug-induced movement disorders. Australian Prescriber 42 (2):56. doi:10.18773/austprescr.2019.014.
   PubMed Web of Science ®Google Scholar
• El-Gaaly, S., P. S. John, S. Dunsmore, and J. M. Bolton. 2009. Atypical neuroleptic malignant syndrome with quetiapine: A case report and review of the literature. Journal of Clinical Psychopharmacology 29 (5):497–99. doi:10.1097/JPC.0b013e3181b4b091.
   PubMed Web of Science ®Google Scholar
• Ferioli, V., A. Manes, C. Melloni, S. Nanni, and G. Bocompagni. 2004. Atypical neuroleptic malignant syndrome caused by clozapine and venlafaxine: Early brief treatment with dantrolene. The Canadian Journal of Psychiatry 49 (7):497–98. doi:10.1177/070674370404900791.
   PubMed Web of Science ®Google Scholar
• Grignon, S., J. Ianic Brethes, M. Chamberland, and D. B. Guimares. 2005. Incipient neuroleptic malignant syndrome with quetiapine/paroxetine combination treatment: Atypical presentation and early, successful rechallenge with olanzapine. International Journal of Psychiatry in Clinical Practice 9 (4):296–98. doi:10.1080/13651500510029110.
   PubMed Web of Science ®Google Scholar
• Guanci, N., R. Aggarwal, and S. Schleifer. 2012. Atypical neuroleptic malignant syndrome associated with iloperidone administration. Psychosomatics 53 (6):603–05. doi:10.1016/j.psym.2012.06.011.
   PubMed Web of Science ®Google Scholar
• Gupta, S., and N. D. Nihalani. 2004. Neuroleptic malignant syndrome: A primary care perspective. Prim care companion. The Journal of Clinical Psychiatry 6:191–94.
   Google Scholar
• Hermesh, H., R. Shiloh, Y. Epstein, H. Manaim, A. Weizman, and H. Munitz. 2000. Heat intolerance in patients with chronic schizophrenia maintained with antipsychotic drugs. American Journal of Psychiatry 157 (8):1327–29. doi:10.1176/appi.ajp.157.8.1327.
   PubMed Web of Science ®Google Scholar
• Kamış, G. Z., Y. Ayhan, K. Basar, S. Ozer, and A. E. A. Yagcioglu. 2014. A case of clozapine intoxication presenting with atypical NMS symptoms. The International Journal of Neuropsychopharmacology 17 (5):819–21. doi:10.1017/S1461145713001624.
   PubMed Web of Science ®Google Scholar
• Kang, S. G., H. J. Lee, M. S. Lee, L. Kim, and J. S. Park. 2006. Atypical neuroleptic malignant syndrome associated with aripiprazole. Journal of Clinical Psychopharmacology 26 (5):534. doi:10.1097/01.jcp.0000237948.88387.d7.
   PubMed Web of Science ®Google Scholar
• Khouri, C., S. Planès, S. Logerot, C. Villier, and M. Mallaret. 2016. Case report: Neuroleptic malignant syndrome and diagnostic difficulties. L’Encéphale 42 (3):277–80. doi:10.1016/j.encep.2016.01.001.
   PubMed Web of Science ®Google Scholar
• Langley-degroot, M., Y. Joshi, D. Lehman, and S. Rao. 2016. Atypical neuroleptic malignant syndrome associated with Paliperidone long-acting injection: A case report. Journal of Clinical Psychopharmacology 36 (3):277–79. doi:10.1097/JPC.0000000000000507.
   PubMed Web of Science ®Google Scholar
• Lee, J. W. 1998. Serum iron in catatonia and neuroleptic malignant syndrome. Biological Psychiatry 44 (6):499–507. doi:10.1016/s0006-3223(98)00109-7.
   PubMed Web of Science ®Google Scholar
• Leonardo, Q. F., G. R. Juliana, and C. J. Fernando. 2017. Atypical neuroleptic malignant syndrome associated with use of Clozapine. Case Reports in Emergency Medicine 2017:2174379. doi:10.1155/2017/2174379.
   PubMedGoogle Scholar
• Leucht, S., A. Cipriani, L. Spineli, D. Mavridis, D. Orey, F. Richter, M. Samara, C. Barbui, R. R. Engel, J. R. Geddes, et al. 2013. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: A multiple-treatments meta-analysis. The Lancet 382 (9896):951–62. doi:10.1016/S0140-6736(13)60733-3.
   PubMed Web of Science ®Google Scholar
• Levenson, J. L. 1985. Neuroleptic malignant syndrome. The American Journal of Psychiatry 142:1137–45.
   PubMed Web of Science ®Google Scholar
• Moher, D., A. Liberati, J. Tetzlaff, and D. G. Altman. 2009. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. Annals of Internal Medicine 151 (4):264–69. doi:10.1016/j.ijsu.2010.02.007.
   PubMed Web of Science ®Google Scholar
• Moscovich, M., F. T. Nóvak, A. F. Fernandes, T. Bruch, T. Tomelin, E. M. Nóvak, R. P. Munhoz, and A. G. Teive. 2011. Neuroleptic malignant syndrome. Arquivos De Neuro-Psiquiatria 69 (5):751–55. doi:10.1590/S0004-282X2011000600005.
   PubMed Web of Science ®Google Scholar
• Murri, M. B., A. Guaglianone, M. Bugliani, P. Calcagno, M. Respino, G. Serafini, M. Innamorati, M. Pompili, and M. Amore. 2015. Second-generation antipsychotics and neuroleptic malignant syndrome: Systematic review and case report analysis. Drugs in R&D 15:45–62. doi:10.1007/s40268-014-0078-0.
   PubMed Web of Science ®Google Scholar
• Neuhut, R., J. P. Lindenmayer, and R. Silva. 2009. Neuroleptic malignant syndrome in children and adolescents on atypical antipsychotic medication: A review. Journal of Child and Adolescent Psychopharmacology 19 (4):415–22. doi:10.1089/cap.20008.0130.
   PubMed Web of Science ®Google Scholar
• Nielsen, J., and A. M. Bruhn. 2005. Atypical neuroleptic malignant syndrome caused by olanzapine. Acta Psychiatrica Scandinavica 112 (3):238–40. doi:10.1111/j.1600-0447.2005.00578.x.
   PubMed Web of Science ®Google Scholar
• Norris, B., V. Angeles, R. Eisenstein, and J. P. Seale. 2006. Neuroleptic malignant syndrome with delayed onset of fever following risperidone administration. Annals of Pharmacotherapy 40 (12):2260–64. doi:10.1345/aph.1H301.
   PubMed Web of Science ®Google Scholar
• Odagaki, Y. 2009. Atypical neuroleptic malignant syndrome or serotonin toxicity associated with atypical antipsychotics? Current Drug Safety 4 (1):84–93. doi:10.2174/157488609787354287.
   PubMedGoogle Scholar
• Oruch, R., I. F. Pryme, B. A. Engelsen, and A. Lund. 2017. Neuroleptic malignant syndrome: An easily overlooked neurologic emergency. Neuropsychiatric Disease and Treatment 13:161–75. doi:10.2147/NDT.S118438.
   PubMed Web of Science ®Google Scholar
• Picard, L. S., S. Lindsay, J. R. Strawn, R. M. Kaneria, N. C. Patel, and P. E. Keck Jr. 2008. Atypical neuroleptic malignant syndrome: Diagnostic controversies and considerations. Pharmacotherapy 28 (4):530–35. doi:10.1592/phco.28.4.530.
   PubMed Web of Science ®Google Scholar
• Rais, A. R., S. Kimmel, N. Shrestha, T. B. Raid, and B. J. Coffey. 2008. Atypical neuroleptic malignant syndrome in an adolescent. Journal of Child and Adolescent Psychopharmacology 18 (2):215–20. doi:10.1089/cap.2008.1821.
   PubMed Web of Science ®Google Scholar
• Reeves, R. R., R. A. Torres, V. Liberto, and R. H. Hart. 2002. Atypical neuroleptic malignant syndrome associated with olanzapine. Pharmacotherapy 22 (5):641–44. doi:10.1592/phco.22.8.641.33211.
   PubMed Web of Science ®Google Scholar
• Sarkar, S., and N. Gupta. 2017. Drug information update. Atypical antipsychotics and neuroleptic malignant syndrome: Nuances and pragmatics of the association. BJPsych Bulletin 41:211–16. doi:10.1192/pb.bp.116.053736.
   PubMed Web of Science ®Google Scholar
• Schreiner, N. M., S. Windham, and A. Barker. 2017. Atypical neuroleptic malignant syndrome: Diagnosis and proposal for an expanded treatment algorithm: A case report. A & A Case Reports 9 (12):339–43. doi:10.1213/XAA.0000000000000610.
   PubMedGoogle Scholar
• Singhai, K., P. P. Kuppili, and N. Nebhinani. 2019. Atypical neuroleptic malignant syndrome: A systematic review of case reports. General Hospital Psychiatry 60:12–29. doi:10.1016/j.genhosppsych.2019.06.009.
   PubMed Web of Science ®Google Scholar
• Spivak, B., D. I. Maline, Y. Vered, V. N. Kozyrev, R. Mester, S. A. Neduva, R. S. Ravilov, E. Graff, and A. Weizman. 2000. Prospective evaluation of circulatory levels of catecholamines and serotonin in neuroleptic malignant syndrome. Acta Psychiatrica Scandinavica 102 (3):226–30. doi:10.1034/j.1600-0447.2000.102003226.x.
   PubMed Web of Science ®Google Scholar
• Strawn, J. R., P. E. Keck, and S. N. Caroff. 2007. Neuroleptic malignant syndrome. American Journal of Psychiatry 164 (6):870–76. doi:10.1176/ajp.2007.164.6.870.
   PubMed Web of Science ®Google Scholar
• Teo, D. C. L., H. K. Wong, and S. N. Tan. 2018. Atypical neuroleptic malignant syndrome precipitated by Clozapine and Quetiapine overdose: A diagnostic challenge. Innovations in Clinical Neuroscience 1:20–22.
   Google Scholar
• Trollor, J. N., X. Chen, K. Chitty, and P. S. Sachdev. 2012. Comparison of neuroleptic malignant syndrome induced by first- and second-generation antipsychotics. British Journal of Psychiatry 201 (1):52–56. doi:10.1192/bjp.bp.111.105189.
   PubMed Web of Science ®Google Scholar
• Tse, L., A. M. Barr, V. Scarapicchia, and F. Vila-Rodriguez. 2015. Neuroleptic malignant syndrome: A review from a clinically orientes perspective. Current Neuropharmacology 13 (3):395–406. doi:10.2174/1570159X13999150424113345.
   PubMed Web of Science ®Google Scholar
• Tseng, P. T., Y. C. Chang, C. H. Chang, H. Y. Wang, Y. S. Cheng, C. K. Wu, Y. W. Chen, and W. Chungl. 2015. Atypical neuroleptic malignant syndrome in patients treated with aripiprazole and clozapine: A case-series study and short review. The International Journal of Psychiatry in Medicine 49 (1):35–43. doi:10.2190/PM.49.1.c.
   PubMed Web of Science ®Google Scholar
• Velamoor, R. 2017. Neuroleptic malignant syndrome: A neuro-psychiatric emergency: Recognition, prevention, and management. Asian Journal of Psychiatry 29:106–09. doi:10.1016/j.ajp.2017.05.004.
   PubMed Web of Science ®Google Scholar
• Verma, K., V. Jayadeva, R. Serrano, and K. Sivashanker. 2018. Diagnostic, treatment, and system challenges in the management of recurrent neuroleptic malignant syndrome on a general medical service. Case Reports in Psychiatry 2018. doi:10.1155/2018/4016087.
   Google Scholar
• Vickery, P. B., L. Meadowcraft, and S. B. Vickery. 2018. Early detection of an atypical presentation of neuroleptic malignant syndrome: A case report. Mental Health Clinician 7 (3):137–42. doi:10.9740/mhc.2017.05.127.
   PubMedGoogle Scholar
• Ware, M. R., D. B. Feller, and K. L. Hall. 2018. Neuroleptic malignant syndrome: Diagnosis and management. The Primary Care Companion For CNS Disorders 20 (1):17r02185. doi:10.4088/pcc/17r02185.
   PubMedGoogle Scholar
• Woo, B. K., and G. V. Obrocea. 2005. Atypical case of neuroleptic malignant syndrome caused by olanzapine and carbamazepine. Psychiatry 2:23–24.
   PubMedGoogle Scholar
• Zhao, Z., H. Zhang, S. Wang, and X. Chen. 2015. Sudden discontinuation and reinstitution of olanzapine-associated atypical neuroleptic malignant syndrome in a patient undergoing lung surgery. International Journal of Clinical and Experimental Medicine 8:11639–41.
   PubMed Web of Science ®Google Scholar